Incidence of arteriovenous thrombosis and the role of anticardiolipin antibodies in hemodialysis patients

被引：10

作者：

Roozbeh Jamshid

Serati Ali Ali Reza

Ghaderi Abbas

Afshariani Raha

机构：

[1] Department of Medicine, Division of Nephrology, Shiraz University of Medical Science, Shiraz

来源：

International Urology and Nephrology | 2003年 / 35卷 / 2期

关键词：

Anticardiolipin antibody; Eprex use; Fistula site; Fistula thrombosis; Hemodialysis;

D O I：

10.1023/B:UROL.0000020354.61227.40

中图分类号：

学科分类号：

摘要：

Introduction: Fistula thrombosis in patients on maintenance hemodialysis is an important morbidity factor. Arterial or venous thrombotic events have been described as complications in patients on regular hemodialysis and positive titers of anticardiolipin antibodies (ACLA). This study was designed to evaluate the prevalence of ACLA in hemodialysis patients and it's relation to arteriovenous fistula (AVF) thrombosis. Methods: 218 patients with AVF on maintenance hemodialysis were studied prospectively during a period of 14 months for any episode of AVF thrombosis (AVFT), after ACLA was assayed by ELISA in 171 ones. Other risk factors for thrombosis such as presence of diabetes, hypotension during dialysis, using of erythropoietin (rEpo), fistula site, gender, age, dialysis duration, and type of dialyser membrane were accessed. Results: 56% of the patients had IgG ACLA = 10 GPL which was significantly correlated with dialysis duration (23.18 ± 24.56 months in patients with ACLA = 10 GPL vs 37.73 ± 36.35 months in patients with 20 = IgG ACLA < 40 GPL). Within 14 months follow up, 39 episodes of AVFT occurred in 34 patients (15.8%). Dialysis duration prior to start of study was 29.16 ± 22.04 months. In our patients radiocephalic AVFs showed more thrombosis than brachiocephalic ones (23% vs 10%, p = 0.01 by Chi-square). Age more than 50 years old was a risk factor for AVFT (p = 0.034 by Chi-square). Also erythropoietin use (p = 0.011 by chi-square) and ultrafiltration more than 3 liters (average value of 14 months) were correlated with AVFT (p = 0.042 by Chi-square), but there wasn't any correlation between diabetes, presence of ACLA, hypotension during dialysis, gender, and dialysis membranes with AVFT. Ultimately, logistic regression analysis of factors associated with thrombosis was done and only fistula site (p = 0.015, O.R. = 2.87), and Eprex use (p = 0.031, O.R. = 4.05) showed significant correlation with AVFT. Conclusion: Although incidence of anticardiolipin antibodies was high in our patients, we found no correlation between IgG ACLA and AVFT. Instead, we found that radiocephalic fistulas and Eprex injection were risk factors for AVFT. © 2004 Kluwer Academic Publishers.

引用

页码：275 / 282

页数：7

共 46 条

[1]

(1997)

[2]

Swedberg S.H., Brown G.B., Sigley R., Wight T.N., Nicholls S.C., Intimal fibromuscular hyperplasia at the venous anastomosis of PTFE grafts in hemodialyis patients, Circulation, 80, 6, pp. 1726-1736, (1989)

[3]

Windus D.W., Jendrisak A., Delmez A., Prosthetis fistula survival and complications in hemodialysis patients: Effects of diabetes and age, Am. J. Kidney Dis., 19, pp. 448-452, (1992)

[4]

Clup K., Flanigan M., Taylor L., Rothstein M., Vascular access thrombosis in new hemodialysis patients, Am. J. Kidney Dis., 26, pp. 341-346, (1995)

[5]

Woods J.D., Turennc M.N., Strawderman R.L., Young E.W., Hirth Ra., Port F.K., Held P.J., Vascular access survival among incident hemodialysis patients in the US, Am. J. Kidney Dis., 30, pp. 50-57, (1997)

[6]

Churchill D.N., Taylor D.W., Cook R.J., Laplante P., Barre P., Cartier P., Fay W.P., Goldstein M.B., Jindal K., Mandin H., Canadian hemodialysis morbidity study, Am. J. Kidney Dis., 19, pp. 214-234, (1992)

[7]

Goldwasser P., Michel M., Collier J., Prealbumin and lipopro(a) in hemodialysis: Relationship with patient and vascular access survival, Am. J. Kidney Dis., 22, pp. 215-225, (1993)

[8]

Fermo I., D'Angelo S.V., Paroni R., Mazzola G., Caroli G., D'Angelo A., Prevalence of moderate hyperhomocysteinemia in patients with early onset of venous and arterial occlusive disease, Ann. Inter. Med., 23, pp. 747-753, (1995)

[9]

Petri H., Rheinshmidt M., Whiting O., Keefe Q., Helman D., Corash L., The frequency of lupus anticoagulant in SLE, Ann. Intern. Med., 106, pp. 524-531, (1987)

[10]

Canoso R.T., Sise H.S., Cholorpromazine induced lupus anticoagulant and associated immunologic abnormalities, Am. J. Hematol., 13, pp. 121-129, (1982)

← 1 2 3 4 5 →